See More Hear More Watch More Hear More Get on iTunes
TIME's The Brief TIMEnewsbrief

New Class of Cholesterol Drugs

The two drugs, evolocumab (under development by Amgen) and alirocumab (under development by Sanofi and Regeneron) appeared to reduce the risk of cardiac events like heart attack by around half, according to new studies. More From The Brief: #FullNewsAudioAvailable


More from